Stoke Therapeutics (STOK) Operating Income Growth (1y) (2019 - 2026)
Stoke Therapeutics (STOK) Operating Income Growth (1y) (2019 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,140.12 Bn | 66,139.83 Bn | - | -24.89% |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.73 Bn | - | - |
| 3 | Akari Therapeutics | 1,022.34 Bn | 1,022.34 Bn | - | - |
| 4 | BeOne Medicines | 472.60 Bn | 467.81 Bn | 1.35 Bn | 2,150.96% |
| 5 | Vertex Pharmaceuticals | 122.34 Bn | 115.09 Bn | 2.59 Bn | 80.62% |
| 6 | Regeneron Pharmaceuticals | 70.14 Bn | 61.39 Bn | 3.31 Bn | 8.65% |
| 7 | Belite Bio | 62.79 Bn | 62.79 Bn | - | - |
| 8 | Argenx Se | 56.19 Bn | 51.00 Bn | 1.41 Bn | 145.20% |
| 9 | Alnylam Pharmaceuticals | 37.50 Bn | 34.49 Bn | 959.66 Mn | 1,386.07% |
| 10 | Stoke Therapeutics | 1.87 Bn | 1.53 Bn | - | -148.02% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -148.02% |
| Dec 31, 2025 | -350.00% |
| Sep 30, 2025 | -43.62% |
| Jun 30, 2025 | 6.96% |
| Mar 31, 2025 | 492.08% |
| Dec 31, 2024 | 53.85% |
| Sep 30, 2024 | -10.17% |
| Jun 30, 2024 | 11.79% |
| Mar 31, 2024 | -14.91% |
| Dec 31, 2023 | -8.87% |
| Sep 30, 2023 | -0.32% |
| Jun 30, 2023 | -31.79% |
| Mar 31, 2023 | 0.42% |
| Dec 31, 2022 | -10.80% |
| Sep 30, 2022 | -19.68% |
| Jun 30, 2022 | -14.57% |
| Mar 31, 2022 | -47.35% |
| Dec 31, 2021 | -68.15% |
| Sep 30, 2021 | -65.44% |
| Jun 30, 2021 | -69.30% |